New vaginal suppository aims to clear HPV and prevent cervical cancer
Disease control
Recruiting now
This study tests an experimental vaginal suppository called Dysplasix in women with high-risk HPV and mild cervical cell changes (ASC-US or LSIL). The goal is to see if the treatment can clear the virus and reverse the abnormal cells. Forty-five women will receive either the acti…
Phase: PHASE2 • Sponsor: Amplexd Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 06:48 UTC